Smith, Kimberly Y <br/><br/>
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.  [electronic resource] 

 -  AIDS (London, England)  Jul 2009 
 - 1547-56 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-5571 
<br/><br/><label>Standard No.: </label>10.1097/QAD.0b013e32832cbcc2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--adverse effects<br/>Adult<br/>Anti-HIV Agents--adverse effects<br/>Antiretroviral Therapy, Highly Active--adverse effects<br/>CD4 Lymphocyte Count<br/>Cardiovascular Diseases--chemically induced<br/>Deoxycytidine--adverse effects<br/>Dideoxynucleosides--adverse effects<br/>Double-Blind Method<br/>Emtricitabine<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--genetics<br/>Humans<br/>Lamivudine--adverse effects<br/>Lopinavir<br/>Male<br/>Organophosphonates--adverse effects<br/>Pyrimidinones--adverse effects<br/>RNA, Viral--blood<br/>Ritonavir--adverse effects<br/>Tenofovir<br/>Treatment Outcome